Monoprost (Latanoprost)

Latanoprost activates prostaglandin F (FP) receptors in the eye, which remodels the extracellular matrix of the ciliary body and increases uveoscleral outflow of aqueous humor. This enhanced drainage lowers intra‑ocular pressure, addressing the primary cause of glaucoma progression.

The prescribed dose of Monoprost is determined by the treating ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but exact dosing and timing should follow the prescriber’s instructions.

Safety data for latanoprost during pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so it should be used only if the potential benefit justifies any potential risk to the fetus or infant.

To order Monoprost, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong IOP‑lowering efficacy. Compared with beta‑blocker drops such as timolol, latanoprost often provides greater pressure reduction with a different side‑effect profile, notably affecting eyelash growth and iris colour.

Monoprost should be stored at room temperature, below 25 °C, in its original packaging. Protect the bottle from direct sunlight and moisture. Do not freeze the solution, and keep the dropper tip clean to avoid contamination.

Monoprost is applied as a single drop into the conjunctival sac of the affected eye(s) once daily, preferably in the evening. Tilt the head back, pull down the lower eyelid to form a pocket, and gently squeeze the bottle without touching the eye or lashes.

Serious adverse events, though rare, include severe eye inflammation such as uveitis or iritis, allergic reactions with swelling or rash, sudden loss of vision, and corneal edema. Patients should seek immediate medical attention if any of these symptoms occur.

Monoprost is contraindicated in individuals with active ocular infections, inflammation, or hypersensitivity to latanoprost or any component of the formulation. Caution is also advised for patients with a history of severe ocular inflammation or those who are pregnant or breastfeeding without clear benefit.